The 8;21 translocation is the most common cytogenetic abnormality in human acute myelogenous leukemia, joining the AML1 gene on chromosome 21, to the ETO gene on chromosome 8, forming the AML1/ETO fusion gene. The AML1/ETO fusion protein has been shown to function mainly as a transcriptional repressor of AML1 target genes and to block AML1 function in vitro and in vivo. However, AML1/ETO can also activate the BCL-2 promoter and cause enhanced hematopoietic progenitor self-renewal in vitro, suggesting gain-of-functions unique to the fusion protein. We used NIH3T3 cells to determine the transforming capacity of AML1/ETO, and to further characterize its mechanism of action. Expression of AML1/ETO in NIH3T3 cells caused cell-type speci®c cell death, and cellular transformation, characterized by phenotypic changes, anchorage-independent growth, and tumor formation in nude mice. In contrast, neither expression of AML1A, AML1B or ETO altered the normal growth pattern of the cells. To investigate the mechanism of transformation by AML1/ETO, we analysed the levels of activated, phosphorylated c-Jun (ser63) and other constituents of the AP-1 complex, in the presence of various AML1/ ETO related proteins. Expression of AML1/ETO increased the level of c-Jun-P (ser63), and activated AP-1 dependent transcription, which was inhibited by expression of a dominant-negative c-Jun protein. Mutational analysis revealed that the runt homology domain (RHD) and a C-terminal transcriptional repression domain in AML1/ETO are required for transformation, activation of c-Jun and increased AP-1 activity. These results establish the transforming potential of the t(8;21) fusion protein and link this gain-of-function property to modulation of AP-1 activity.
Introduction
Identi®cation of the genes at the breakpoints of several of the most commonly occurring cytogenetic abnormalities in acute myelogenous and acute lymphocytic leukemia has revealed a convergence on the core binding factor (CBF) transcription factor complex (Sawyers, 1997) . The t(8;21), inv(16), t(12;21), and t(3;21) all target the CBF complex, which normally consists of a heterodimer between the AML1/CBFa subunit, which binds DNA in a sequence speci®c manner (Meyers et al., 1993) and a non-DNA binding subunit, CBFb (Ogawa et al., 1993; Wang et al., 1993) . The (8;21) translocation, which is associated with the M2 FAB subtype of acute myelogenous leukemia (AML) and occurs in approximately 10 ± 20% of AML cases, juxtaposes the AML1 gene on chromosome 21, to the ETO gene on chromosome 8, resulting in an AML1/ETO fusion gene (Erickson et al., 1992; Miyoshi et al., 1993) . Identical AML1/ETO fusion transcripts have been detected in all cases in which the t(8;21) is found , however, the role of the fusion protein in leukemogenesis has not been elucidated.
The AML1 protein is a member of the runt family of transcription factors, de®ned by a region of homology to the Drosophila melanogaster segmentation gene runt (termed RHD for runt homology domain) (Daga et al., 1992; Miyoshi et al., 1991) , which mediates DNA binding and interacts with Bro and BigBro, which are the Drosophila versions of CBFb (Golling et al., 1996) . The consensus DNA sequence recognized by AML1, TGT/cGGT (Meyers et al., 1993) , is contained in the promoter and enhancer regions of many hematopoietic-speci®c genes . Although murine genes encoding AML2 and AML3 have been identi®ed (Levanon et al., 1994) , an essential role for AML1 in hematopoiesis was demonstrated by AML1 (Okuda et al., 1996; Wang et al., 1996a) and CBFb (Niki et al., 1997; Sasaki et al., 1996; Wang et al., 1996b) knock-out experiments. Mice that lack AML1 or CBFb have absent fetal liver hematopoiesis and die between days E11.5-13.5 with a distinct pattern of central nervous system hemorrhage. Although the function of ETO is unknown, the protein shares several regions of homology with the Drosophila protein nervy, which is expressed exclusively in the nervous system (Feinstein et al., 1995) . ETO is expressed in CD34 + cells (Erickson et al., 1996) ; it has recently been reported to physically associate with the transcriptional repressor N-CoR (Wang et al., 1997a) .
The ability of AML1/ETO to aect normal AML1 function was ®rst shown in transient transfection assays, which demonstrated that AML1/ETO can function as a dominant-negative regulator of AML1B mediated transcriptional activation (Frank et al., 1995; . Evidence for an in vivo dominantnegative function of the fusion protein was provided by AML1/ETO knock-in experiments, which showed that mice heterozygous for AML1/ETO had the same phenotype as AML1 knock-out mice (Okuda et al., 1998; Yergeau et al., 1997) . Consistent with a negative eect on AML1 function, AML1/ETO has been shown to block both the dierentiation of myeloid progenitor cell lines and the ability of AML1 to activate myeloid speci®c promoters (Kitabayashi et al., 1998; Westendorf et al., 1998) . In contrast to its role as a dominant inhibitor, AML1/ETO can activate the BCL-2 promoter in U937 cells, an eect not seen when AML1 or ETO are overexpressed in these cells (Klampfer et al., 1996) . AML1/ETO expression in a knock-in model, and in retrovirally transduced murine bone marrow stem cells, caused increased progenitor cell self-renewal capacity and dysplastic hematopoiesis (Okuda et al., 1998) . Although these experiments indicate that AML1/ETO can alter normal cellular growth properties, its ability to cause transformation has not been demonstrated.
NIH3T3 cells have been utilized to demonstrate the transforming potential of both classical oncogenes and leukemia-speci®c fusion transcription factors (Kamps et al., 1991; Monica et al., 1994; Yoshihara et al., 1995) . Although both AML1 and ETO have been reported to be capable transforming these cells, we have found that only AML1/ETO can function as a transforming oncogene in NIH3T3 cells. Expression of AML1/ETO also had an early lethal eect on the cells, which was not seen with expression of AML1 or ETO. Transformation assays utilizing deletion mutants of AML1/ETO demonstrated that both the runt homology domain, and C-terminal sequences are critical to its transforming activity. Transformation by AML1/ ETO resulted in increased levels of phosphorylated cJun (ser63), which correlated with activation of an AP-1 responsive promoter (the human collagenase type 1 promoter). In addition, this activation was blocked by co-expression of a dominant negative c-Jun protein.
These ®ndings provide evidence that in the process of leukemogenesis, AML1/ETO may not only function to block myeloid dierentiation, but may also directly contribute to neoplastic transformation; they also implicate the c-Jun oncoprotein as a mediator of the gain-of-function properties of AML1/ETO.
Results
Expression of AML1/ETO, AML1 proteins and ETO in NIH3T3 cells; morphologic changes are induced only by AML1/ETO The AML1 gene encodes several alternatively spliced isoforms: AML1A is 250 amino acids in length and lacks a C-terminal transactivation domain (Miyoshi et al., 1991) ; AML1B/AML1c (479 aa) Miyoshi et al., 1995) and AML1b (453 aa) (Miyoshi et al., 1995) have dierent amino-and carboxy-terminal amino acids but both contain an intact RHD and a putative C-terminal transactivation domain. Overexpression of AML1b but not AML1A was previously reported to be able to transform NIH3T3 cells (Kurokawa et al., 1996) . It has also been reported that ETO has transforming abilities (Wang et al., 1997b) . Therefore, in addition to determining if AML1/ETO can transform NIH3T3 cells, we compared the relative transforming abilities of the fusion protein with AML1 and ETO.
We utilized retroviral gene transfer to obtain high level expression of the transduced proteins, and to enable rapid analysis of polyclonal cell populations in order to avoid clonal variation. AML1/ETO, AML1A, AML1B and ETO proteins ( Figure 1a) were expressed from the pSRa vector ®rst in 293T cells (using DNA transfection) and then in NIH3T3 cells after retroviral infection (multiplicity of infection of ®ve), as demonstrated by Western blot analysis. Figure 1b demonstrates expression of the 94 kDa AML1/ETO protein, the 53 kDa AML1B protein and the 32 kDa AML1A protein in pooled G418 resistant NIH3T3 cells. Expression of the 75 kDa ETO protein is demonstrated in Figure 4a (lane 6). Expression of AML1/ ETO in transfected 293T cells and in the t(8;21) containing Kasumi-1 cell line (Asou et al., 1991) (Figure 1b, lanes 1 and 2) , served as controls to verify the molecular size and integrity of the expressed proteins.
Approximately 6 days after infection of 1610 5 NIH3T3 cells (ATCC) with the AML1/ETO retroviral supernatant, total cell numbers began to decline, accompanied by an increase in dying cells ( Figure  2a ). Cells infected with the empty retrovirus (Neo), or virus expressing AML1A, AML1B, or ETO did not exhibit these changes (all had the same morphology as Neo expressing cells, Figure 2a ). Median cell counts on day 6 were 4.5610 5 for the AML1/ETO expressing cells vs 4.5610 6 for the Neo cells. This eect was seen independently of the presence of G418 in the growth media.
The surviving cells transduced with AML1/ETO grew either as rounded cells, which detached from the dish, or as spindle shaped, refractile cells growing at high cell densities. The latter cells became the predominant cell type after 14 days of growth in G418 (Figure 2a ). In contrast, cells expressing Neo, AML1A, AML1B or ETO maintained a normal morphology, remaining¯at and contact inhibited (Figure 2a ). Consistent with their neoplastic phenotype, cells expressing AML1/ETO achieved saturation densities three times that of control and AML1B or ETO expressing cells (Table 1) . As a control for transformation, cells infected with an activated N-ras expressing virus acquired the typical fusiform morphology and grew exponentially, without the growth inhibitory eects seen with AML1/ETO (data not shown).
Expression of AML1/ETO, but not AML1 or ETO confers anchorage-independent cell growth and tumorigenicity on NIH3T3 cells NIH3T3 cells (ATCC) that stably expressed AML1/ ETO formed macroscopic colonies in soft agar, which varied considerably in size ( Figure 2b and Table 1 ). In contrast, cells stably expressing Neo, AML1A (not shown), AML1B, or ETO formed neither macroscopic nor microscopic colonies in soft agar ( Figure 2b and Table 1 ). Thus, only AML1/ETO imparts anchorageindependent cell growth to NIH3T3 cells.
To determine the in vivo oncogenicity of AML1/ETO, AML1B and ETO, NIH3T3 cells expressing the proteins were injected subcutaneously into the¯anks of nude mice. Four out of four sites injected with AML1/ETO expressing cells developed tumors, with a latency period of one week; these tumors grew to 41 cm in diameter by 6 weeks of observation (Table 1) . Intact AML1/ETO protein expression was con®rmed in the tumor tissue by Western blot analysis (data not shown). Sites injected with AML1B or ETO expressing cells did not develop tumors. One of the four sites injected with NIH3T3-Neo cells developed a tumor at 5 weeks, which was 1 cm in size by 7 weeks (Table 1) .
Because overexpression of AML1/ETO in NIH3T3 cells obtained from the ATCC resulted in both cell death and transformation, we analysed the eects of AML1/ETO using a more uniform population of 3T3 cells. Renshaw et al. (1995) isolated a clonal population of NIH3T3 cells from the Lewis clone 7 cell line, termed P-3T3, which was transformable by BCR/ABL. We repeated the transformation studies described above in P-3T3 cells; expression of AML1/ETO resulted in a transformed morphology, characterized by spontaneous detachment of the cells from the dish (Figure 3) . Expression of Neo, AML1B or ETO did not alter the morphology of the cells (Figure 3 ) and only the P-3T3 cells that expressed AML1/ETO formed colonies in soft agar (Table 1) , and AML1A protein expression in total cellular extracts of pooled G418 resistant, retrovirally infected, NIH3T3 cells (last four lanes). 293T cells transfected with the pSRa vector encoding AML1/ETO and Kasumi-1, a t(8;21) containing cell line that expresses AML1/ETO and AML1B were used as positive controls (lanes 1 and 2, respectively). Proteins were detected using an a-AML1 antisera. Molecular size markers are indicated on the left tumors with an average latency of 3 weeks (Table 1) . Neither AML1B, ETO nor Neo expressing cells formed tumors by 8 weeks of observation.
These results demonstrate that expression of AML1/ ETO in NIH3T3 cells leads to in vitro and in vivo transformation and provide direct evidence that the fusion protein, but not the wild type proteins, is oncogenic.
Structure/function analysis of AML1/ETO
To de®ne the domains of AML1/ETO (A/E) required for its transforming activity, we tested three mutants, which have been demonstrated to lack speci®c transcriptional activities compared to the intact protein ( Figure 1a ): A/E-D401 lacks the ability to transcriptionally activate the bcl-2 gene promoter (Klampfer et al., 1996) , although it can repress transcription Westendorf et al., 1998) ; A/E-D292 does not repress AML1B mediated transactivation of the TCRb enhancer ; A/E-DRHD can neither bind DNA nor interact with CBFb . Expression of the three intact mutant proteins in NIH3T3 cells, at the expected molecular weights, was demonstrated by Western blot analysis (Figure 4a ).
Expression of A/E-D401 resulted in morphological transformation of P-3T3 cells (data not shown), although these cells did not spontaneously detach from the dish, as was observed with the AML1/ETO expressing cells. Cells expressing A/E-D401 were able to grow in an anchorage-independent manner, although they formed fewer colonies than AML1/ ETO expressing cells (Figure 4b ). Cells expressing the mutant proteins A/E-D292 and A/E-DRHD were neither morphologically transformed nor able to form a signi®cant number of colonies in soft agar ( Figure  4b ). These results indicate that the C-terminal domain of AML1/ETO (ETO aa. 402 ± 575; A/E aa 579 ± 752) is not essential for transforming activity. ETO sequences between residues 469 ± 579 of AML1/ETO and the RHD in the AML1 portion, are essential for transformation by the fusion protein.
NIH3T3 cells transformed by AML1/ETO exhibit increased levels of phosphorylated c-Jun (ser63)
To gain insight into the potential signaling pathways utilized by AML1/ETO to transform NIH3T3 cells, we analysed the levels of both total and N-terminal phosphorylated c-Jun (ser63) in cells stably expressing the various AML1/ETO-related proteins. As shown in Figure 5a , expression of AML1/ETO resulted in constitutively elevated levels of phosphorylated c-Jun protein compared with cells expressing Neo, AML1B or ETO, analysed at 7 or 14 days after retroviral infection. Cells from the ATCC and the P-3T3 subline exhibited similar patterns of c-Jun phosphorylation (data shown only for P-3T3 cells). A direct relationship between transformation by AML1/ETO and the levels of c-Jun-P (ser63) was further indicated by the ®nding that only the AML1/ETO deletion mutant that retained transforming potential, A/E-D401, generated an increased amount of c-Jun-P (ser63), although this was less than that found in cells expressing AML1/ ETO (Figure 5a ). Total c-Jun levels were comparable for all the cell lines tested, indicating that AML1/ETO did not signi®cantly alter c-jun expression, although increases in total c-Jun protein levels were occasionally seen in cells expressing AML1/ETO and A/E-D401 (data not shown), attributed to autoactivation of c-jun expression as a result of the increased levels of c-Jun-P (ser63). As a control for c-Jun phosphorylation, NIH3T3 cells stably expressing activated N-ras exhibited high levels of c-Jun-P (ser63) (Figure 5a ). Equivalent levels of CDK4 protein were detected in each sample, which served to control for protein loading (Figure 5a ).
An analysis of other potential constituents of the AP-1 complex did not reveal signi®cant dierences in AML1/ETO stimulates AP-1 transcriptional activity, which requires c-Jun
To distinguish between a direct eect of AML1/ETO on AP-1 proteins from that occurring secondary to the transformation process, we analysed the eects of the various AML1/ETO proteins on AP-1 transcriptional activity after transient transfection of cells, prior to the onset of phenotypic changes associated with cellular transformation. As shown in Figure 6a , AML1/ETO activated the AP-1 responsive Col-Z-Luc reporter plasmid (which contains an AP-1 site from 773 to +66, but no AML1 binding sites) by approximately sevenfold. In contrast, neither AML1B nor ETO altered the promoter activity of this plasmid. Of the deletion mutants of AML1/ETO tested, only A/E-D401 increased collagenase promoter activity (4 ± 6-fold), whereas A/E-DRHD had no eect (Figure 6a ). These results directly correlate with the levels of activated cJun protein expression (Figure 5a ): the two constructs that increase c-Jun-P levels in the retrovirally infected cell lines, AML1/ETO and A/E-D401, are the only two constructs that increase AP-1 activity. Additionally, the promoter activity of the Col-Z-Luc plasmid in NIH3T3 cells stably expressing AML1/ETO was increased compared to that in Neo expressing cells, after correcting for dierences in the transfection efficiencies of these cell lines (data not shown).
To determine if AML1/ETO mediated activation of the AP-1 response element requires c-Jun activity, we tested whether the TAM-67 dominant-negative mutant of c-Jun (DNJ) could inhibit transactivation by AML1/ETO. As shown in Figure  6b , co-expression of DNJ with AML1/ETO eliminated the activation of the reporter plasmid. Expression of DNJ with the control pSRa vector slightly decreased the basal activity of Col-Z-Luc. These results demonstrate that activation by AML1/ETO of the human collagenase promoter, which lacks an AML1 binding site, requires c-Jun activity.
Discussion
The AML1:CBFb transcription factor complex is disrupted by the most common cytogenetic abnormalities found in human leukemia and therefore, elucidating its functional properties will result in a better understanding of both normal and leukemic hematopoiesis. The AML1 gene is fused to dierent genes depending on the chromosomal abnormality: to ETO in the t(8;21), resulting in an AML1/ETO fusion gene (Miyoshi et al., 1993) ; to EVI-1 in the t(3;21), resulting in AML1/EVI-1 (Mitani et al., 1994) ; to TEL in the t(12;21), resulting in TEL-AML1 (Golub et al., 1995; Romana et al., 1995) . The CBFb subunit is altered in the inv(16) chromosomal abnormality, to form a CBFb-MYH11 fusion protein (Liu et al., 1993) . Both AML1/ETO (Okuda et al., 1998; Yergeau et al., 1997) and CBFb-MYH11 (Castilla et al., 1996) knock-in mice fail to develop de®nitive hematopoiesis, suggesting that the fusion proteins could account for the block in dierentiation characteristic of AML. However, because of the lethal phenotype of the knock-in mice, the role of the fusion proteins in leukemogenesis has remained unclear.
In this report, we show that expression of AML1/ ETO in NIH3T3 cells results in an altered cell morphology and growth pattern, anchorage-independent cell growth, and in vivo tumorigenicity, providing evidence that the fusion protein can function as an oncogene. The RHD, which mediates both DNA binding and dimerization with CBFb, is critical for the transforming function of AML1/ETO. A/E-D401, which lacks the C-terminal zinc ®nger domain and one proline-serine/threonine rich region, retains transforming potential, whereas A/E-D292 does not. Previous studies have shown that a mutant similar to A/E-D401 can repress TCRb enhancer activity, but that the A/E-D292 mutant does not repress transcription Kitabayashi et al., 1998) . Neither of these mutants can upregulate BCL-2 promoter activity (Klampfer et al., 1996) , suggesting that transforming activity correlates best with the ability of AML1/ETO to repress transcription of AML1B activated promoters. A recent mutational analysis of AML1/ETO identi®ed the 292 ± 401 aa region as being essential for the ability of AML1/ETO to block the differentiation and G-CSF dependent proliferation of L-G murine myeloid progenitor cells and to interact with the MTGR1 protein (Kitabayashi et al., 1998) . Thus, studies of AML1/ETO in numerous cell types demonstrate the importance of the 292 ± 401 a.a. region of AML1/ETO to its biological functions.
The ability of AML1/ETO to transform NIH3T3 cells (and to cause early cell death) represents another function not possessed by its AML1 or ETO constituents. We have previously shown that truncation of AML1 at amino acid 177 is not sucient for its transcriptional regulatory properties (Uchida et al., 1997) , and numerous functional domains have been identi®ed in the ETO portion of the fusion protein (Lutterbach et al., 1998; Kitabayashi et al., 1998) . Several novel biologic functions acquired by the fusion protein were recently demonstrated in AML1/ETO knock-in and retrovirally transduced murine stem cell experiments, in which AML1/ETO expression resulted in dysplastic hematopoiesis and increased progenitor cell self-renewal capabilities. To investigate the mechanisms utilized by AML1/ETO to transform NIH3T3 cells, we have shown that transformation tightly correlates with the intracellular levels of phosphorylated c-Jun (ser63) and with the ability to activate AP-1 mediated transcription. Furthermore, we demonstrated that this activation was eliminated by coexpression of a dominant-negative c-Jun protein. The N-terminus of c-Jun contains the transactivation domain, which is essential for its transforming activity (Lloyd et al., 1991; Smeal et al., 1991) , and phosphorylation of ser63/ser73 leads to increased AP-1 activity (Karin et al., 1997) . Thus, AML1/ETO may promote aberrant cell growth and dierentiation by causing the constitutive activation of relevant c-Jun/ AP-1 target genes.
These ®ndings extend the link between alterations in AP-1 activity and the expression of leukemia-speci®c fusion proteins, previously described for PML/RARa (Doucas et al., 1993) , AML1/EVI-1 (Kurokawa et al., 1995; Tanaka et al., 1995a) , and BCR/ABL (Mandanas et al., 1993) . The relationship between AML1/ETO and AP-1 activation diers from that for AML1/EVI-1, in that neither wild type constituent of AML1/ETO activates AP-1 whereas, the wild type EVI-1 protein activates it to a greater extent than AML1/EVI-1. Also, the RHD domain in AML1/EVI-1 was not required for activation of AP-1 (Tanaka et al., 1995a) . We identi®ed c-Jun as one of the major activated AP-1 species in cells expressing AML1-ETO. In studies with the BCR/ABL chimeric oncoprotein, BCR/ABL increased AP-1 activity, activated JNK and required c-Jun for transformation (Raitano et al., 1995) . We are currently investigating the roles of the dierent MAP kinase pathways, and the requirement for c-Jun, in transformation caused by AML1/ETO.
We also compared the transforming potential of AML1/ETO with AML1 and ETO and found that neither AML1A, AML1B nor ETO altered the normal cell growth pattern, despite being expressed at high levels as a result of retroviral transduction. These ®ndings are consistent with the observation that AML1 and ETO proteins are expressed in normal human hematopoietic cells (Erickson et al., 1996) , whereas AML1/ETO is expressed only in leukemic blasts. It remains possible that the wild type proteins can enhance the transforming eects of the fusion protein, as it has been shown that AML1/ETO and AML1B can synergistically transactivate the M-CSFR promoter (Rhoades et al., 1996) ; this possibility will be tested in future transformation assays.
Our ®nding that AML1B is non-transforming in NIH3T3 cells diers from that of Kurokawa et al. (1996) who found that AML1b transforms these cells. It remains possible that AML1b (453 aa) has transforming potential but that AML1B (479 aa) does not, but these contrasting ®ndings may be due to experimental dierences in assay conditions or the source of NIH3T3 cells used (although AML1A was non-transforming in both assays). Therefore, we performed transformation assays in NIH3T3 cells from two dierent sources, polyclonal cells from the ATCC and the P-3T3 subclone of the Lewis clone 7 cell line. We demonstrated that in both cell lines, only AML1/ETO had transforming properties. By studying the various AML1 proteins in the same assay, we can conclude that the oncogenic potential of AML1/ETO is signi®cantly greater than that of AML1B. Overexpression of AML1b in the hematopoietic cell line 32D eliminated the block to dierentiation imposed by overexpressed AML1A (Tanaka et al., 1995b) ; this eect would be consistent with an inability of AML1b to transform cells.
The transforming potential of ETO was also tested in the NIH3T3 transformation assay and ETO failed to induce morphologic alteration, anchorage independent growth or tumorigenicity in nude mice, using two dierent sources of 3T3 cells. This is in contrast to a report in which ETO expression induced a low number of soft agar colonies, using clonally selected cells which were also able to form tumors in splenectomized/ irradiated nude mice (Wang et al., 1997b) . It is likely that the dierent cell selection procedures and assay conditions employed account for the disparate results. The functional importance of ETO amino acids in the fusion protein may be revealed by the recent ®nding that ETO physically interacts with the nuclear corepressor. N-CoR (Wang et al., 1997a) , which links transcriptional repression by AML1/ETO to a global repressor complex involving mSin3A and histone deacetylase (HDAC) (reviewed in Pazin and Kadonaga, 1997; Wole, 1997) . Deletion mutant analysis of AML1/ETO has now demonstrated a direct relationship between transformation, activation of AP-1 target genes, and transcriptional repression of AML1 target genes . This suggests that AML1/ ETO recruitment of the N-CoR/mSin3A/HDAC complex results in both transcriptional repression and transformation. The mechanism by which AML1/ETO activates AP-1 dependent transcription is unknown but may involve titration of repressor molecules; alternatively, AML1/ETO may downregulate the transcription of a cellular phosphatase involved in JNK regulation, resulting in enhanced N-terminal phosphorylation of cJun.
The expression of AML1/ETO in NIH3T3 cells also caused cell death in a substantial fraction of the polyclonal cells from the ATCC, but not the P-3T3 cell line, an eect consistent with its function as an oncogene. Several genes implicated in oncogenesis have been shown to induce either transformation or apoptosis, including c-myc (Askew et al., 1991 , Evan et al., 1992 , activated N-ras (Darley et al., 1997) and cjun (Bossy-Wetzel et al., 1997) , often in a cell-type dependent fashion. Expression of other leukemiaassociated chimeric oncoproteins, such as E2A/PBX1 (Smith et al., 1997) and PML/RARa (Ferrucci et al., 1997) can induce apoptosis of hematopoietic cells, yet their expression is clearly tolerated in the leukemic cell. We have similarly found that the myeloid cell lines 32Dc13, FDCP-1, and HL-60 do not tolerate constitutive expression of AML1/ETO (Frank et al., unpublished data) .
In summary, we have found that the t(8;21) fusion protein, AML1/ETO, can promote cellular transformation, N-terminal phosphorylation of c-Jun and transcriptional activation of AP-1 responsive promoters, which represent gain-of-function properties that are distinct from the well established negative eects of AML1/ETO on AML1 function. Further investigation into the interrelationship among leukemia-speci®c fusion proteins and AP-1 transcription factors may reveal that common biochemical pathways are important to the pathogenesis of several distinct types of human leukemia.
Materials and methods

Construction of expression vectors
The full length cDNAs encoding AML1A, AML1B and AML1/ETO ( Figure 1a ) were subcloned by blunt ended ligation into the EcoRI site of the retroviral expression vector pSRaMSVtkneo (kindly provided by Owen Witte). The full length ETO cDNA (Figure 1a) , corresponding to the MTG8a isoform (Miyoshi et al., 1993) , was constructed by PCR ampli®cation of a 465 bp fragment using the ETO speci®c oligonucleotides 5'-ACGCGTCGACATGCCT-GATCGTACTGAGAAGCACTCC-3' and 5'-AAAAAT-GGGATGACAAAAGGT-3' and the AML1/ETO cDNA in pBS + as a template. The PCR product was sequenced and subcloned into the SalI and SpeI sites of AML1/ETO and the resultant full length ETO cDNA was subcloned into pSRa. AML1/ETO mutant cDNAs (Figure 1a) are numbered based on the number of amino acids from ETO contained in the fusion protein. They include: A/E-D401, which lacks 174 C-terminal amino acids (including the zinc ®nger domain) and was constructed by digestion at a unique EcoRI site (residue 579); A/E-D292, which lacks 283 C-terminal amino acids (including the transcriptional repression domain , constructed by digestion at a unique AvaII site (residue 469); and A/E-DRHD, containing a 40 amino acid deletion in the runt homology domain, constructed by removal of a 120 bp AvrII ± Bsu361 restriction fragment from AML1. The activated N-ras cDNA, containing a mutation in codon 12 (glycine?aspartate) was isolated from the vector pLNras (kindly provided by Geo Symonds and Karen MacKenzie) by digestion with BglII and HindIII; it was subcloned into pSRa by blunt ended ligation.
Generation of retroviral stocks
Retroviral stocks (replication defective) were generated by transient transfection of 293T cells (obtained from the American Type Culture Collection) (Pear et al., 1993) . Approximately 2610 6 293T cells were seeded onto 6 cm 2 dishes, and transfected by the calcium phosphate method the following day using 8 mg each of the ecotropic packaging vector C 7 -E-MLV (kindly provided by Owen Witte) and the various pSRa constructs. Culture supernatant viral stocks were harvested at 24 and 48 h, ®ltered through 0.45 mm ®lters (Whatman) and stored at 7708. Viral titers were determined on NIH3T3 cells selected in G418 (750 mg/ml); approximately 5610 5 c.f.u./ml were used per infection (titers of AML1/ETO retroviral stocks were approximately tenfold lower, attributed to a toxic eect of the fusion protein).
Cell culture and transformation assays
Contact-inhibited NIH3T3 cells were obtained from the ATCC. The P-3T3 subclone cell line was kindly provided by Jean Wang (Renshaw et al., 1995) . All lines were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with penicillin (100 U/ml), streptomycin (100 mg/ ml) and 10% bovine calf serum (Hyclone) and were split at subcon¯uence. For retroviral infection, 1610 5 NIH3T3 cells were incubated for 4 h with 293T cell viral supernatants and 8 mg/ml polybrene (Sigma). Forty-eight hours after infection, G418 was added (at a concentration of 750 mg/ml) and the cells were analysed after 2 weeks of selection. For all studies, pooled populations of G418 resistant cells were used to avoid clonal variation; each experiment was performed at least three times (i.e., independent viral infections). Cell morphology was assessed by light and phase microscopy using an Olympus CK2 inverted microscope. Soft agar assays were performed in 35 mm dishes by plating 2610 4 ± 1610 5 cells in DMEM with 5% fetal calf serum in 0.4% agar on a 0.6% agar base. Macroscopic colonies were scored 2 weeks after plating. NIH3T3 cells infected with the N-ras expressing retrovirus served as a positive control for the transformation assays. For saturation density analysis, 10 5 cells were seeded in DMEM with 10% calf serum in 35 mm dishes and cultured for up to 10 days. The cells were counted manually, in duplicate, using a hemocytometer. Tumorigenicity assays were performed by subcutaneously injecting 5610 5 (ATCC) or 8610 5 (P-3T3) cells into the¯anks of 8 ± 12 week old athymic nude (nu/nu) mice, obtained from Jackson Laboratories (Bar Harbor, Maine, USA). The mice were inspected weekly for the development of tumors, observed for 7 ± 8 weeks, and were euthanized when tumors reached a diameter of 1.5 cm.
Immunoblotting
Stably transduced NIH3T3 cells and transiently transfected 293T cells were lysed in SDS buer containing protease inhibitors (125 mM TrisCl, 4% SDS, 200 mM DTT, 20% glycerol, 1 mg/ml aprotinin, 5 mg/ml leupeptin, 1 mg/ml pepstatin) and equal numbers of cells were loaded onto SDS ± PAGE gels (10%) and transferred to nitrocellulose ®lters. AML1 proteins were detected with an anity puri®ed a-AML1 antisera, raised against the 17 Nterminal amino acids of AML1 (kindly provided by Scott Hiebert), and ETO proteins were detected with an ETOspeci®c antibody (kindly provided by Paul Erickson). Antibodies to total c-Jun, phosphorylated c-Jun (ser63), JunB, Fos proteins and CDK4 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to total and phosphorylated AFT-2 (Thr71) were obtained from New England Biolabs (Beverly, MA, USA). Western blots were developed using the ECL kit (Amersham) and exposed to ®lm for 30 ± 60 s.
Transcriptional analysis
The Col-Z-Luc plasmid, containing promoter sequences from 71200 to +63 of the human collagenase type 1 gene cloned upstream of the luciferase reporter gene, has been previously described (Kurie et al., 1993) and was kindly provided by Ethan Dmitrovsky. For transient transfection assays, NIH3T3 cells were transfected by the calcium phosphate method using the ProFection kit from Promega (Madison, WI, USA). 2610 5 cells were placed into each well of a six well plate (Falcon) and, the next day, were transfected with 5 mg of pSRa expression vector, 0.5 mg reporter plasmid and 0.5 mg pSVb-galactosidase, which was included as an internal control for transfection eciency. The dominant-negative c-Jun (DNJ) expression vector, CMV-TAM67 , was kindly provided by Michael Birrer. Experiments with DNJ included the addition of 5 mg of CMV-TAM67 or the empty CMV5 vector. The media was changed 12 h after transfection and the cells were harvested 36 h later. Both luciferase and bgalactosidase activities were determined using kits from Promega. Luciferase activity was quantitated in a Lumat luminometer (Berthold) and b-galactosidase activity was measured at 420 nM in a Genesys 5 spectrophotomer (Spectronic). Luciferase units were normalized with respect to b-galactosidase activities.
Note added in proof Wang et al. have recently localized the region in ETO responsible for interacting with N-CoR to the zinc ®nger domain (Proc. Natl. Acad. Sci. USA, 1998, 95: 10860) . Therefore transformation by AML1/ETO may not require this interaction with N-CoR
